Polymeric Nanosuspensions for Enhanced Dissolution of Water Insoluble Drugs

Table 2

Amount of polymers used in nanosuspension formulations.

Drug	Sample label	Organic phase; PEG-300; (wt%)	Aqueous phase; HPMC/PVP (ratio 1 : 1) (wt%)
NIF	A1	43.36	4.32
	A2	31.16	31.2
	A3	23.77	47.54
	A4	16.11	64.44
CBZ	A1	42.01	4.2
	A2	30.48	30.5
	A3	23.36	46.72
	A4	15.92	63.68
IBP	A1	42.01	4.2
	A2	30.48	30.5
	A3	23.36	46.72
	A4	15.92	63.68